Call us: + 31 (0)20 - 4350 580

Home > News > Blog

Blog

Combination immunotherapy: The latest revolution in cancer treatment

Combination immunotherapy: The latest revolution in cancer treatment
13 September 2018 - Romy Krikke BSc

An analysis of the clinical landscape The present focus in the treatment of cancer is immunotherapy, in particular immunotherapies that are trialed in a combination regimen. By combining immuno-oncology (IO) agents with oth...

Read more

ASCO 2018 recap - pembro the way to go?

ASCO 2018 recap - pembro the way to go?
11 June 2018 - Lindy Bosch MSc., Business Development

The 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) gathered over 32.000 oncology professionals from all over the world, highlighting the latest in cancer care treatments.

Read more

AACR2018 - Emerging trends in next generation immunotherapy

AACR2018 - Emerging trends in next generation immunotherapy
25 April 2018 - Nadina Grosios PhD MPH, Yuva Oz MSc.

Chicago hosted the 2018 annual meeting of the American Association for Cancer Research (AACR) in its cold spring days. As expected, enthusiasm centered on immunotherapy combination therapy and its challenges, and the possibilit...

Read more

The future of data management in clinical trials - ACDM 2018

The future of data management in clinical trials - ACDM 2018
11 April 2018 - José Matamoros Luna MSc., Clinical Data Manager

On March 13, Brussels was considered the capital of Data Management, hosting the annual conference of the Association for Clinical Data Management (ACDM). Since technologies and standards continue to evolve in the ever changing...

Read more

Power of targeted, personalized and combined therapies - TAT 2018

Power of targeted, personalized and combined therapies - TAT 2018
9 March 2018 - Yuva Oz MSc., Business Development

The home of Phase I oncology conference a.k.a. the Targeted Anticancer Therapies (TAT) conference took place this week in the beautiful city of Paris. The program is dedicated to early-phase development and translational resear...

Read more

EMA anticancer drug recommendations for approval in 2017

EMA anticancer drug recommendations for approval in 2017
23 January 2018

In 2017, the European Medicines Agency (EMA) made a total of 92 positive recommendations to the European Commission for medicines to receive marketing approval. Approximately one fourth (23/92) were aimed at cancer treatment, w...

Read more

No child should die of cancer: paediatric oncology trials in Europe and USA

No child should die of cancer: paediatric oncology trials in Europe and USA
12 December 2017 - José Matamoros Luna, Clinical Data Manager

Paediatric oncology has in general been one of the most successful areas of oncology where current treatments can achieve good efficacy and long term survival. However, this is still not the case for a significant number of chi...

Read more

Are you ready for the new EudraVigilance System?

Are you ready for the new EudraVigilance System?
1 November 2017

The new system has implications for all users of the EudraVigilance system, such as National Competent Authorities, Marketing Authorisation Holders and Sponsors of clinical trials. All users have to ensure that their processes...

Read more

CICON2017: Translating Science into Survival #3

CICON2017: Translating Science into Survival #3
20 September 2017

Over the week we will publish a blog mini-series of each day's key highlights from the Third CRI-CIMT-EATI-AACR (CICON17) International Cancer Immunotherapy Conference: Translating Science into Survival (September 6-9, 2017 in...

Read more

CICON2017: Translating Science into Survival #2

CICON2017: Translating Science into Survival #2
19 September 2017

Over the week we will publish a blog mini-series of each day's key highlights from the Third CRI-CIMT-EATI-AACR (CICON17) International Cancer Immunotherapy Conference: Translating Science into Survival (September 6-9, 2017 in...

Read more

CICON2017: Translating Science into Survival #1

CICON2017: Translating Science into Survival #1
15 September 2017

Over the week we will publish a blog mini-series of each day's key highlights from the Third CRI-CIMT-EATI-AACR (CICON17) International Cancer Immunotherapy Conference: Translating Science into Survival (September 6-9, 2017 in...

Read more

The year after; was the CRA-academy really the gateway to become a great CRA?

The year after; was the CRA-academy really the gateway to become a great CRA?
22 June 2017

So here we are again, already more than a year later since we participated in SMS-oncology's first CRA-academy. Might sound cliché but time indeed seems to fly when you are having fun. We certainly enjoyed the past year, and mo...

Read more

Compassionate Use: providing cancer care outside trials

Compassionate Use: providing cancer care outside trials
2 May 2017

Being a challenging and arduous operation, finding new therapies to treat cancer often is a time-consuming process. For some patients, marketed therapies are to no avail, while at the same moment new optional therapies are on t...

Read more

The changing landscape of oncology clinical trials - AACR 2017

The changing landscape of oncology clinical trials - AACR 2017
14 April 2017

The 2017 annual meeting of the American Association for Cancer Research (AACR) could not start any better. A fascinating plenary session included Angela Belcher (Massachusetts Institute of Technology) and Bert Vogelstein (Sidne...

Read more

EMA anticancer drug recommendations for approval in 2016

EMA anticancer drug recommendations for approval in 2016
27 January 2017

Among the 81 medicines recommended for approval by the Committee for Medicinal Products for Human Use (CHMP) in 2016, there were 13 recommendations made for novel oncology products, just slightly down from 16 in the previous ye...

Read more

ESMO 2016 - upcoming themes in oncology drug development

ESMO 2016 - upcoming themes in oncology drug development
17 October 2016

If you have not visited the ESMO conference for some years, you might be astonished by the rapid growth this conference has seen. This year's attendance was well over 20,000 persons and therefore not only the largest ESMO ever,...

Read more

SMS-oncology takes part in Ride for the Roses

SMS-oncology takes part in Ride for the Roses
9 September 2016

Congratulations to "De vier Ds" team, our SMS-oncology colleagues Nadina, Philine, Fleur, Stephan, Miraj, Julia and Yuka, for taking part in the Ride for the Roses on Sunday 4th September to help raise money for cancer research...

Read more

The gateway to become a great CRA; personal CRA-academy experience

The gateway to become a great CRA; personal CRA-academy experience
20 July 2016

So here we are, all five of us being part of different project teams and excited about performing our first visits as Clinical Research Associates (CRAs). Already a few months ago, we participated in SMS-oncology's first CRA-ac...

Read more

"Woman v Cancer" Ride the Night

"Woman v Cancer" Ride the Night
31 May 2016

We are very proud of and would like to congratulate our colleague Nadina Grosios for fundraising and taking part in the "Women v Cancer" Ride The Night 100 Km cycle challenge through London last weekend, 28th May 2016, in suppo...

Read more

CIMT 2016 - Rise of mRNA therapeutics, a relatively new class of treatment

CIMT 2016 - Rise of mRNA therapeutics, a relatively new class of treatment
24 May 2016

The increase of titles related to RNA-based therapeutics and vaccines within the CIMT poster session compared to previous years, highlighted the increased focus on RNA approaches. Therefore, some details will be given in this s...

Read more
1 2 3 next